# US 2024/0197875 A1 · Novel method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197875 A1
- Document ID: US20240197875A1
- Status: Published application
- Kind: A1
- Application number: 18/554,501
- Filed: 2022-04-08
- Published: 2024-06-20
- Earliest claimed: 2021-04-09
- Assignees: GammaDelta Therapeutics Ltd
- Applicants: Gammadelta Therapeutics Limited
- Inventors: Andrew John HUTTON; Istvan KOVACS; Oliver NUSSBAUMER
- Web page: https://patentgrep.com/patent/US20240197875A1

## CPC

- A61K 40/4255: {Mesothelin [MSLN]}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2502/11: blood or immune system cells
- C12N 2502/1114: T cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to methods for expanding γδ T cells comprising preparing a composition enriched for γδ T cells and culturing the composition in the presence of feeder cells. Also provided is a method for engineering γδ T cells comprising preparing a composition enriched for γδ T cells, transducing the composition to express a chimeric antigen receptor (CAR) specific for a tumour associated antigen and culturing the transduced composition to expand the engineered γδ T cells. Also provided are expanded and engineered γδ T cells produced according to the described methods, which find utility in adoptive T cell therapies, chimeric receptor therapies and the like.

## Claims

### Claim 1

A method for expanding γδ T cells, wherein said method comprises the steps of:
(i) preparing a composition enriched for γδ T cells; and
(ii) culturing the composition in the presence of feeder cells, wherein the feeder cells are present in a ratio of at least 4:1 (feeder cells: γδ T cells).

### Claim 2

A method for expanding γδ T cells, wherein said method comprises the steps of:
(i) preparing a composition enriched for γδ T cells; and
(ii) culturing the composition in the presence of feeder cells and media comprising IL-15 and IL-21, wherein the feeder cells are present in a ratio of at least 3:2 (feeder cells: γδ T cells).

### Claim 3

A method for expanding γδ T cells, wherein said method comprises the steps of:
(i) preparing a composition enriched for γδ T cells by depletion of αβ T cells; and
(ii) culturing the composition in the presence of feeder cells, wherein the feeder cells are present in a ratio of at least 3:2 (feeder cells: γδ T cells).

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the feeder cells are present in a ratio of at least 4:1 (feeder cells: γδ T cells).

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1 to 4, wherein the feeder cells are present in a ratio of at least 10:1 (feeder cells: γδ T cells).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein the feeder cells are present in a ratio of about 10:1 to about 99:1 (feeder cells: γδ T cells).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1 to 6, wherein the feeder cells comprise αβ T cells.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the αβ T cells comprise CD4 T cells.

### Claim 9 (depends on 7, 8)

The method according to claim 7 or claim 8, wherein the feeder cells additionally comprise Natural Killer (NK) cells.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1 to 9, wherein the feeder cells are irradiated.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1 to 10, wherein the feeder cells are derived from non-haematopoietic tissue.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the feeder cells are derived from skin.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the feeder cells are derived from a single donor.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the feeder cells are derived from multiple donors.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1 to 14, wherein the γδ T cells are derived from a single donor.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1 to 14, wherein the γδ T cells are derived from multiple donors.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method according to any one of claims 1 to 16, wherein the feeder cells and the γδ T cells are derived from the same donor(s).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method according to any one of claims 1 to 16, wherein the feeder cells and the γδ T cells are derived from different donor(s).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1 to 18, wherein the method comprises removing the feeder cells from the expanded γδ T cells by depletion of αβ T cells.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1 to 18, wherein the method comprises removing the feeder cells from the expanded γδ T cells by positive selection of γδ T cells.

### Claim 21

A method for engineering γδ T cells, said method comprising the steps of:
(i) preparing a composition enriched for γδ T cells;
(ii) transducing the composition to express a chimeric antigen receptor (CAR) recognizing a tumour antigen in the absence of TCR stimulation; and
(iii) culturing the transduced composition to expand the engineered γδ T cells,
wherein steps (ii) and (iii) may be performed in either order or concurrently.

### Claim 22 (depends on 21)

The method according to claim 21, wherein step (ii) is performed prior to step (iii).

### Claim 23 (depends on 21)

The method according to claim 21, wherein step (ii) is performed concurrently with step (iii).

### Claim 24 (depends on 21, 22, 23)

The method according to any one of claims 21 to 23, wherein the composition is transduced using a viral vector, such as a retroviral vector, such as a gammaretroviral vector or a lentiviral vector.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the viral vector is a gammaretroviral vector, such as murine stem cell virus (MSCV) or Moloney Murine Leukemia Virus (MLV).

### Claim 26 (depends on 24, 25)

The method according to claim 24 or claim 25, wherein the viral vector is pseudotyped with an envelope other than vesicular stomatitis virus-G (VSV-G), for example a betaretroviral envelope such as baboon endogenous virus (BaEV) or RD114.

### Claim 27 (depends on 24, 25, 26)

The method according to any one of claims 24 to 26, wherein step (ii) is performed using 1×107 TU/ml of viral vector.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method according to any one of claims 21 to 27, wherein the tumour antigen is a tumour specific antigen that is not expressed by normal somatic cells from the subject tissue.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27)

The method according to any one of claims 21 to 27, wherein the tumour antigen is a tumour associated antigen which is preferentially overexpressed on cancer cells compared to healthy somatic cells.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27)

The method according to any one of claims 21 to 27, wherein the tumour antigen is an antigen expressed in the context of stress events such as oxidative stress, DNA damage, UV radiation, EGF receptor stimulation.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method according to any one of claims 21 to 30, wherein the tumour antigen is an antigen associated with a solid tumour.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the solid tumour is a mesothelin+ tumour.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 21 to 32, wherein the tumour associated antigen is mesothelin.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 21 to 33, wherein step (iii) comprises culturing the transduced composition in the absence of feeder cells.

### Claim 35 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 21 to 33, wherein step (iii) comprises culturing the transduced composition in the presence of feeder cells.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 32)

The method according to claim 32 comprising the steps of a method according to any one of claims 1 to 20.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method according to any one of claims 1 to 36, wherein step (i) comprises depletion of αβ T cells from a mixed cell population obtained from a starting sample.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method according to any one of claims 1 to 36, wherein step (i) comprises positive selection of γδ T cells from a mixed cell population obtained from a starting sample.

### Claim 39 (depends on 37, 38)

The method according to claim 37 or claim 38, wherein the starting sample is human tissue.

### Claim 40 (depends on 37, 38, 39)

The method according to any one of claims 37 to 39, wherein the starting sample is non-haematopoietic tissue.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the starting sample is skin.

### Claim 42 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method according to any one of claim 1 or 3 to 41, wherein the composition is cultured in media comprising IL-15 or IL-21.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the media comprises IL-15 and IL-21.

### Claim 44 (depends on 42, 43)

The method according to any one of claim 42 or 43, wherein the media additionally comprises IL-2 and/or IL-4

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 1 to 44, wherein the method comprises culturing the composition for between 7 and 21 days.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method according to any one of claims 1 to 45, wherein the method comprises culturing the composition for about 10, 11, 12, 13, or 14 days.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 1 to 42, wherein expanding the population of γδ T cells provides at least a 5-fold, especially at least a 10-fold, in particular at least a 20-fold, such as at least a 50-fold, for example at least a 100-fold number of γδ T cells.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method according to any one of claims 1 to 47, wherein the method comprises freezing the expanded γδ T cells.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

An expanded γδ T cell population obtainable, such as obtained, by the method of any one of claims 1 to 20 or 36 to 48.

### Claim 50 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

An engineered γδ T cell population obtainable, such as obtained, by the method according to any one of claims 21 to 48.

### Claim 51 (depends on 48, 50)

A pharmaceutical composition comprising the expanded γδ T cell population according to claim 48 or engineered γδ T cell population according to claim 50.

### Claim 52 (depends on 49, 50, 51)

The expanded γδ T cell population according to claim 49, the engineered γδ T cell population according to claim 50 or the pharmaceutical composition according to claim 51 for use as a medicament.

### Claim 53 (depends on 49, 50, 51)

The expanded γδ T cell population according to claim 49, the engineered γδ T cell population according to claim 50 or the pharmaceutical composition according to claim 51 for use in the treatment of cancer.

### Claim 54 (depends on 53)

The expanded γδ T cell population, engineered γδ T cell population or pharmaceutical composition for use according to claim 53, wherein the cancer is a solid tumour.
